Dr. Pérez has more than 29 years experience in pharmaceuticals including Head of Development of Anti-Infectives at Novartis and at Roche´s spin-off, Basilea Pharmaceutica, both in Basel, Switzerland; Almirall (Head of Development) and Esteve (Medical Director and Board member), Barcelona, Spain. Nowadays he is consultant for drug development. In some companies is acting as Chief Medical Officer, Medical Director or Chairman of the Advisory Board. 
 

Lídia has a degree in Biochemistry and she is Qualified European Patent Attorney (EQE-2014). She is a professional with 15 years experience in Intellectual Property, especially in the fields of biotechnology and biomedicine. She has held different positions at a university technology transfer office, at a law firm working as patent advisor, in the private sector working as chief IP officer and as a professor in this area. She has gained experience and knowledge in all technical aspects related to patents (e.g. state of the art analysis, patentability and freedom-to-operate reports, patent drafting, patent prosecution, due dilligence) but also in the management of patent portfolios, patent lifecycle and in defining strategies aligned with company's business and research. Besides her knowledge of the European patent system, her knowledge in patent systems of around 20 different countries gives her a global vision. She has recently created her own project of patent consultancy, Patent Riders. Lídia works for Ability Pharmaceuticals as external IP Manager, managing all the aspects of IP of the company.  

Albert holds a Bachelor of Law degree (University of Barcelona, Spain) and also a Juris Doctor of Law degree (accredited by The American Bar Association, USA). He has been a member of the Barcelona Bar Association for more than 10 years and he specializes in Intellectual Property rights, as well as innovation and entrepreneurship, focusing on the Life Sciences and Healthcare. He regularly advises companies in the technological and biotechnological sector, mainly in the area of research and development, as well as in the protection, exploitation and transfer of their technology. He also has extensive experience in litigation and transactions relating to patents, designs, trademarks, trade secrets, know-how and unfair competition. Albert is involved in many technological companies as an external legal advisor. 

Esperanza Regueras obtained a degree in Pharmacy at Univerity of Navarra in Pamplona and a MBA at IESE business school in Barcelona. For more than 8 years she has worked as employee in pharmaceutical companies in a multinational environment. In 2004, following its entrepreneurship instints, she founded Axis Pharma firm, specialized in strategic consulting and market research services for pharmaceutical companies worldwide. Axis Pharma has provided its services to more than 20 big multinationals and has helped many biotech companies and R&D groups. Its large experience in a such a innovative sector has provided to her a deep background in innovation and improvement.

Dr. Ramesh is a Veterinarian, board-certified Regulatory Professional and board-certified Toxicologist & Pharmacologist with 18 years of pharmaceutical industry, GLP and non-clinical CRO experience. He is an expert in regulatory strategy and safety assessment of small molecules of new molecular entities (NCE) and reformulated (505b2) drugs. He has a track record of rapidly moving early-stage drugs into clinical development (IND) and eventual NDA. He has managed non-clinical safety programs for several new and reformulated drugs and was responsible for over 25 IND/NDA, including oral solids, injectables, topicals and ophthalmic drugs.  
 

He provides strategic and tactical leadership on toxicology issues affecting drug development programs. He has extensively worked on toxicological risk assessment of chemicals/drugs, environmental risk assessment, evaluation of extractables and leachables, computational toxicology evaluations, qualification of organic and inorganic impurities/excipients, nitrosamines and setting limits for genotoxic/carcinogenic compounds.
 

He is currently president of Regulatory and Non-Clinical Consultancy and provides advice to start-ups on non-clinical development and regulatory strategy. He previously held Senior Toxicologist (SME) positions with pharmaceutical companies and CROs including Advinus Therapeutics Ltd., Vivo Biotech, Dr. Reddy’s Laboratories and Eurofins Scientific.

Dr Kerr graduated in 1989 with a PhD in Chemistry from Glasgow University and has 35+ years of experience in Pharmaceutical Development, gained from successfully developing and launching NCEs. He spent 28 years in senior leadership roles at AstraZeneca in Process R&D, API Manufacturing and Supply Chain and has worked across all phases of the product lifecycle. On leaving AstraZeneca, Fraser established Astute Pharma Associates, a consultancy company which advises Biotechs on all aspects of Manufacturing Science & Technology and also undertakes Due Diligence in support of asset and facility acquisitions.

He is a Fellow of the Royal Society of Chemistry, coach for European Innovation Council Accelerator Programme and a business advisor for the Innovate UK ICURe Programme.

Roger Torrent obtained his Chemical Engineering Degree at the Institut Quimic de Sarrià (IQS), Barcelona, and he is currently Senior Consultant for national and international public grants. He joined Inveready in 2012 and his work focuses on identifying, preparing and monitoring public funding for innovative business projects, and R&D lines, both nationally and internationally.
 
Previously, he worked as a grant manager for 4 years at the biotechnology firm AB-Biotics, a probiotics and pharmacogenetics company in the field of neurospiquiatría, obtaining financing for the development of their projects, and accompanying it from its initial stages until the exit to the alternative stock market. He has also worked as a consultant in the Euro-Funding firm, specialized in obtaining public funds for business development projects.